Replimune Group, Inc. (REPL)
| Market Cap | 878.07M -7.6% |
| Revenue (ttm) | n/a |
| Net Income | -313.94M |
| EPS | -3.38 |
| Shares Out | 83.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,792,173 |
| Open | 10.71 |
| Previous Close | 10.75 |
| Day's Range | 10.27 - 10.98 |
| 52-Week Range | 1.50 - 12.50 |
| Beta | 0.87 |
| Analysts | Hold |
| Price Target | 10.67 (+2.01%) |
| Earnings Date | Aug 3, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for REPL stock is "Hold." The 12-month stock price target is $10.67, which is an increase of 2.01% from the latest price.
News
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 3,199 puts trading, or 1.5x expected. Most active are Sep-26 18 puts and Aug-26 8 puts, with total volume in those strikes…
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Replimune Group, Inc. (NASDAQ: REPL) against certain...
Replimune Group Proxy statement: Proxy filing
Replimune Group filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 2,615 puts trading, or 1.8x expected. Most active are Aug-26 7 puts and 8/7 weekly 15 calls, with total volume in those…
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 5,913 puts trading, or 3x expected. Most active are 8/14 weekly 8 puts and 8/7 weekly 8 puts, with total volume in…
Replimune price target raised to $9 from $6 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $9 from $6 and keeps a Neutral rating on the shares. The firm notes the company reported fiscal fourth quarter…
BMO double upgrades Replimune on higher chances of FDA approval
BMO Capital double upgraded Replimune (REPL) to Outperform from Underperform with a price target of $16, up from $1. The FDA’s acceptance of Replimune’s re-filed application increased confidence in RP...
Replimune Group put volume heavy and directionally bearish
Bearish flow noted in Replimune (REPL) Group with 1,899 puts trading, or 1.4x expected. Most active are Aug-26 7 puts and Aug-26 15 calls, with total volume in those strikes…
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Group Earnings release: Q4 2026
Replimune Group released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
Replimune Group Annual report: Q4 2026
Replimune Group has published its Q4 2026 annual report on June 29, 2026.
JPMorgan upgrades Replimune on RP1 application resubmission
JPMorgan upgraded Replimune (REPL) to Overweight from Neutral with a price target of $17, up from $8, after the company announced that the RP1 biologics license application resubmission has been…
Replimune upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Replimune (REPL) to Overweight from Neutral with a $17 price target
Replimune announces FDA acceptance of RP1 biologics license application
Replimune (REPL) announced that the FDA has accepted for review the resubmission of the biologics license application, or BLA, for RP1 in combination with nivolumab for the treatment of advanced…
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced t...
Replimune Group trading resumes
09:35 EDT Replimune (REPL) Group trading resumes
Replimune Group trading halted, volatility trading pause
09:30 EDT Replimune (REPL) Group trading halted, volatility trading pause
Replimune price target raised to $6 from $2 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $6 from $2 and keeps a Neutral rating on the shares. The firm notes the company announced resubmission and reconsideration…
Replimune presents final first-in-human data for RP2 alone, with nivolumab
Replimune (REPL) Group presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society…
Replimune presents 3-year overall survival data from IGNYTE trial
Replimune (REPL) Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the…
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presen...
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presen...
How Replimune's drug got a third chance after the White House intervened
Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune said it plans to resubmit its melanoma drug for approval following two earlier rejections. The move follows the departure of Food and Drug Administration Commissioner Marty Makary.
Replimune reaches agreement with US FDA to resubmit melanoma drug application
Replimune said on Friday it it has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental skin cancer drug after the re...